 |
|
Effect of Rimonabant on Weight and Cardiometabolic Risk Factors—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Patients were not excluded from the RIO trials based on their baseline Hospital Anxiety and Depression score. As shown in the Table, 272 patients had a subscore for depression between 8 and 10, and 64 had a subscore of 11 or higher at baseline in the RIO studies. However, consistent with National Institutes of Health recommendations,1 patients for whom weight loss therapy is not appropriate were not entered in the study (patients with a serious uncontrolled psychiatric illness such as major uncontrolled depression).
Table appears in full text version.
|
|
|
|
Table. Depression Subscores on the Hospital Anxiety and Depression Scale for Participants in the RIO-Europe, RIO-Lipids, RIO-Diabetes, and RIO-North America Trials
|
|
|
Most patients presenting with a normal subscore for depression of 7 or less at baseline had a normal subscore at follow-up. A small proportion, equally distributed in the placebo group and in the 20 mg of rimonabant daily group, shifted to a depression . . . [Full Text of this Article]
F. Xavier Pi-Sunyer, MD
fxp1@columbia.edu
Obesity Research Center
St Luke's-Roosevelt Hospital
Columbia University College of Physicians and Surgeons
New York, NY
RELATED ARTICLES
Effect of Rimonabant on Weight and Cardiometabolic Risk Factors
Kishore M. Gadde
JAMA. 2006;296(6):649-650.
EXTRACT
| FULL TEXT
Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial
F. Xavier Pi-Sunyer, Louis J. Aronne, Hassan M. Heshmati, Jeanne Devin, Julio Rosenstock, and for the RIO-North America Study Group
JAMA. 2006;295(7):761-775.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks
Gadde and Allison
Circulation 2006;114:974-984.
FULL TEXT
|
